Background: Oxidative stress is presumed to impair -adenoceptor function and airway patency. Erdosteine (E), a mucomodulatory compound, has shown important antioxidant properties. Methods:The objective was to assess the effect of antioxidant interventions on short-term airway response to salbutamol in non-reversible mild-to-moderate COPD patients. Thirty COPD patients (GOLD class 1-2), current smoker (!10 pack/year), randomly received E 300 mg, N-acetylcysteine (NAC) 600 mg, or placebo, twice daily for ten days. Reversibility to salbutamol 200 mg was tested in baseline, after four and ten days of each treatment. ROS and 8-isoprostane blood levels were measured on the same days. Between-treatment comparison was performed by ANOVA and t-test or Wilcoxon test, and p50.05 assumed. E enhanced FEV1 reversibility after four and ten days significantly (þ5.1% and þ5.0%; both p50.01 vs. placebo), while NAC only showed a transient effect at day 4 (þ3.0%, p50.05), but not at day 10 (þ1.3%, p ¼ ns).
Introduction
Chronic obstructive pulmonary disease (COPD) is a progressive condition characterized by airflow limitation which is largely irreversible. Oxidative stress and chronic lung inflammation are major hallmarks in the pathogenesis of COPD, and affect several determinants of lung pathology (e.g. neutrophil lung recruitment, antiprotease inactivation, mucus hypersecretion, alveolar injury, remodelling of extracellular matrix, membrane lipid peroxidation) [Rahman, 2005] .
An increase of reactive species of oxygen and pro-inflammatory cytokines has been shown to affect 2 receptor function through a series of biological events leading to impaired airway smoothmuscle response to 2 -adrenergic agonists. These mechanisms contribute to the poorer responses to 2 -adrenergic stimulation in chronic inflammatory airway conditions [van Hoof et al. 2003; Koto et al. 1996] .
In view of the relevant role played by oxidative stress in the pathogenesis of COPD, increasingly more attention is given to novel therapeutic approaches that can target the oxidant/antioxidant imbalance occurring in this disease [Rahman, 2006] .
Erdosteine is a molecule originally developed as a mucolytic agent which is characterized by a blocked thiol group in a lactone ring which becomes available for pharmacogical activity after its metabolization to the active metabolite 1 (Met I) [Miyake et al. 1999] .
At present, erdosteine is currently used for treating acute and chronic pulmonary diseases due to its rheological activity on bronchial secretions [Marchioni et al. 1990] , and its positive effects on bacterial adhesiveness [Braga et al. 1999] . Several preclinical studies have recently demonstrated a strong antioxidant activity of this drug in different animal models [Moretti and Marchioni, 2007] . Moreover, in a placebo-controlled study carried out in young healthy smokers, a four-week treatment with erdosteine significantly reduced the acute effect of cigarette smoking on serum thiobarbituric acid reactive substance (TBARS), which is a marker of oxidative cellular injury [Basyigit et al. 2005] .
A recent controlled study carried out vs. placebo in smoker COPD patients showed that erdosteine is able to affect significantly (such as decrease) reactive oxygen species (ROS), eNO and some pro-inflammatory cytokines (IL-8 and TNF) compared with placebo [Dal Negro et al. 2005] . Moreover, erdosteine also reduced plasma levels of 8-isoprostane, which is a marker of lipid peroxidation, after ten days of treatment [Dal Negro et al. 2008] .
The aim of the present study was to investigate if erdosteine protection against the effects of oxidative stress and lipid peroxidation could affect the short-term airway response to salbutamol in non-reversible mild-to-moderate COPD patients.
Material and methods
This was a randomized, placebo-controlled, parallel group study carried out in 30 COPD patients (GOLD stage I-II), current smokers, with a cigarette consumption of more than ten packs/year. Written informed consent was obtained prior to the study start-up. Only shortacting 2 -agonists pro re nata were allowed during the study period; short-acting 2 adrenergics were stopped 8-12 hours before each reversibility test.
Inhaled steroids (ICS) were not allowed, and the very few patients who had been treated with ICS (n ¼ 3) stopped ICS assumption eight weeks before the study start-up. Obese and diabetic subjects, and subjects with a diagnosis and/or history of asthma and a positive reversibility test (a 200 ml absolute, and a412% FEV 1 change from baseline after salbutamol 200 mg) were excluded.
Patients were randomized to receive oral erdosteine 300 mg (E), N-acetylcysteine 600 mg (N) or placebo (P) twice daily for ten days. Spirometry was performed before and 30 min after inhalation of salbutamol 200 mg in baseline, after four and after ten days of each treatment. FEV 1 response to salbutamol was expressed as percentage change predicted value. ROS and 8-isoprostane levels in peripheral blood were also measured at the same experimental times.
ROS concentrations were measured immediately after the blood collection by means of a monochromatic light absorbency spectrophotometer at a constant temperature of 37 C (Callegari, Parma, Italy). Values were expressed as Fort units (1 FU, the oxidative power of 0.26 mg/l H 2 O 2 ), being normal values 300 FU [Dal Negro et al. 2003 ]. Concentrations of 8-isoprostane were measured by an automated immunoanalyser (Immulite Õ , DPC, USA), being values expressed as pg/ml.
Patients were carefully instructed to report any change in their health status occurring during the study period. Moreover, all subjects were carefully instructed (and also provided with written instruction) to limit the consumption of fresh vegetables during the study, and to avoid this kind of food during the 24 hours before the test. The occurrence of adverse event during treatments was recorded at each visit. The study was in agreement to the Helsinki Declaration (as currently amended), and the ICH E6 Good Clinical Practice (GCP) Consolidated Guidance.
Descriptive statistics were summarized by treatment group as means (AESD), and 95% confidence intervals (CIs) for the mean changes from baseline were calculated for all parameters. Data were analysed according to the general linear model (GLM) procedure. Analysis of variance (ANOVA) was performed considering time, treatments and the interaction time*treatments as sources of variability. The between-treatment comparison at each observation time was performed by Student's t-test. The primary objective was FEV 1 reversibility values at day 10 in the erdosteine group compared to placebo, all other comparisons and variables being considered as secondary objectives. ROS and 8-isoprostane concentrations during treatments were expressed as percentage changes from baseline; the Mann-Whitney U-test was used for statistical comparison between treatments. The accepted level of statistical significance was p50.05.
Results

Subjects
All patients completed the study. No patient reported any relevant adverse event, and general tolerability of treatments was very good indeed. Basal characteristics of the study population by treatment group are summarized in Table 1 . The study groups were matched for age, sex, smoke history and clinical features. All patients had spirometric evidence of COPD and blood ROS levels exceeding the upper limit for normality (higher than 300 FU). Mean BMI of the whole sample of subjects was 24.6 AE 2.1.
FEV 1 response to salbutamol The increase of FEV 1 after salbutamol was negligible in all treatment groups in baseline. The FEV 1 response to salbutamol was significantly enhanced after four and ten days of only erdosteine treatment: changes were from 1.38% AE 4.4 (% pred.) in baseline, to 6.45% AE 4.3 and 6.42% AE 4.2, respectively. No significant change was seen during and after both NAC and placebo treatments. Compared with baseline, it corresponded to an absolute difference of þ0.146 l (95% CI: À0.002; 0.294) and þ0.141 l (95% CI: 0.065; 0.217) at day 4 and day 10, respectively, in terms of volumetric response to salbutamol. Mean changes from baseline (and 95% CIs) in FEV 1 increase observed after salbutamol in all treatment groups of patients (as % pred. and as volume difference) are reported in Table 2 .
Statistical comparison vs. placebo showed a significant difference at both time-points (p ¼ 0.0038 and p ¼ 0.0047, respectively) for erdosteine, while NAC showed a transient effect at day 4, but not at day 10 (p ¼ 0.029 and p ¼ 0.58, respectively) ( Figure 1 ).
Moreover, a slight increase of FVC values was also observed after salbutamol inhalation in patients assuming erdosteine (ÁFVC: from À0.002 l in baseline to 0.147 l at day 10). No significant changes were seen in the placebo and in the NAC group of subjects.
ROS and 8-isoprostane in peripheral blood
In contrast to placebo, erdosteine and NAC progressively and significantly reduced ROS blood levels starting from day 4, and values were close to the normal limits after ten days of both treatments. A significant treatment (p50.0001) and time (p ¼ 0.0288) effects were shown by ANOVA, with a time-treatment interaction also significant (p ¼ 0.0029). The statistical comparison versus placebo showed a significant difference at both timepoints for erdosteine and NAC, as reported in Figure 2 .
Blood concentrations of 8-isoprostane were significantly lower than baseline during the ten-day treatment with erdosteine, while the slight reduction induced by NAC at day 4 became negligible six days later. There were no changes in the placebo group. There was a significant treatment effect (p50.001), whereas ANOVA did not prove any significant time effect or significant time-treatment interaction.
The statistical comparisons showed a significant difference for the percentage reduction obtained with erdosteine after four and ten days compared to placebo (p ¼ 0.0173 and p ¼ 0.0004, respectively), while the changes observed during NAC treatment did not reach statistical significance versus placebo (p ¼ 0.064 and p ¼ 0.0539) (Figure 3 ).
Discussion
The results of the present study confirm the efficacy of erdosteine in reducing blood levels of 
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reactive oxygen species in subjects where oxidative stress is prominent, such as in COPD patients who were still active smokers. The strong scavenging properties of erdosteine, as already documented in previous studies in vitro [Braga et al. 2000] , in several animal models on free-radical oxidant damage [Moretti and Marchioni, 2006] , and also in clinical settings [Basyigit et al. 2005; Dal Negro et al. 2005] , are also further confirmed in smoker COPD patients. Furthermore, the substantial minimisation of ROS to nearly normal blood values as occurring since the first days of treatment also contribute to support the fast onset of erdosteine antioxidant activity. N-acetylcysteine, used as a positive control, exerted a comparable effect in terms of reduction of ROS levels in blood in agreement with its well known in vitro and in vivo antioxidant activity [Dekhuijzen, 2005] .
Data from the present study also provide additional evidence on the capability of erdosteine of inhibiting lipid peroxidation, as shown by the substantial decrease induced in 8-isoprostane, which is a specific marker of this function. This peculiar effect is in agreement with data collected in a previous study carried out on a comparable patients' sample [Dal Negro et al. 2005 ]. Figure 2 . Reduction of ROS concentrations in peripheral blood during a ten-day treatment with erdosteine and NAC (between-treatment comparison). Data are mean (SE). Mann-Whitney U-test: **p50.001 and ***p50.0001 vs placebo; erdosteine vs NAC ns.
In particular, the drop in 8-isoprostane proved to occur according to a time-course is somehow different (such as delayed) from that of the ROS decrease. In fact, the statistical significance vs. placebo was achieved only after ten days of treatment. In contrast to erdosteine, N-acetylcysteine only induced a transient decrease in 8-isoprostane levels at day 4 of treatment, but this effect became negligible and disappeared only a few days later.
Even though the exact pharmacological mechanisms of erdosteine action on function of cell membranes should be further investigated and more precisely defined, present data seem to support the hypothesis that erdosteine can be characterized as different from NAC because it seems to be endowed with properties that go beyond the sole and already known scavenging effects on ROS.
The most relevant evidence from the present paper is, however, represented by the systematic and clinically relevant enhancement of bronchial response following 2 -adrenergic administration that was uniquely proved following erdosteine treatment. To our knowledge, this peculiar feature of erdosteine activity was never previously described.
The mean net FEV 1 increase of about 160 ml after salbutamol as observed after four and ten days of treatment with erdosteine represents a fairly good achievement in patients with COPD who had been previously documented as non-responding to the short-acting 2 -adrenergic drug. Consistent with this knowledge, all patients in the present study had a mean basal level of reversibility ranging from þ1% to þ2.4% predicted. Only patients treated with erdosteine consistently increased their response to salbutamol to a value of þ6.45% over the ten days of treatment, whereas NAC effect proved only transient and clinically negligible from this point of view.
As the effect of erdosteine on ROS was quite similar to that of NAC, it is unlikely that the peculiar effect of erdosteine on short-term FEV 1 reversibility after salbutamol will be merely explained on the basis of its scavenging activity.
As suggested by the clear activity on 8-isoprostane plasma levels, the protection exerted by erdosteine against lipid peroxidation might rather be suggested as the main drive of this particular effect.
Although the mechanisms underlying bronchial reversibility in COPD have not been fully elucidated, it has been reported that patients with poorer reversibility of their airflow limitation show higher glutathione (GSH) and protein oxidation, while both IL-6 and TNF-are increased in plasma and sputum. This would suggest that the loss of airflow reversibility may be associated with a condition of enhanced oxidative stress/inflammation [Serviddio et al. 2006 ]. Interestingly, in a large cohort of patients with mild-to-moderate COPD a marked increase of bronchodilator reversibility was observed in the subgroup of sustained quitters of smoking compared to intermittent quitters and continuous smokers, leading authors to speculate that smoking cessation had mediated a potential for bronchodilation by reducing airway inflammation [Serviddio et al. 2006 ].
FEV 1 responses observed in another study [Anthonisen et al. 2005] , in terms of both absolute and percentage predicted values, were numerically in line with present data, and are supporting the consistency of our observations. In fact, the extent of improvement in lung function induced in the present study by erdosteine should not be disregarded as not clinically relevant, just considering the importance of even a small gain in respiratory function for COPD patients (particularly for the severe subjects) who are basically characterised by an irreversible functional condition. The role of lung function, and of volume and flow reversibility in predicting disease progression of COPD (e.g. rate of lung function; health status decline, and rate of exacerbations) has been already clarified [Serviddio et al. 2006; Calverley et al. 2003 ]: obviously, an improved response to bronchodilators is presumed to impact positively in COPD patients in terms of daily symptoms and quality of life [Omata et al. 2007 ].
Since 2 -adrenoceptor sensitivity proved affected by antioxidant interventions in our study, the hypothesis that the function of 2 adrenergic receptors may be reduced in the presence of strong oxidizing conditions seems to be confirmed, as well as the potential efficacy of compounds like erdosteine as an additional drug in the disease management of COPD. Furthermore, in agreement with previous in vitro data [Dal Sasso et al. 2002] , a synergistic effect of erdosteine and 2 -agonists may be postulated.
In conclusion, data from the present study confirms that increased oxidative stress conditions as expected in current smokers with mild-to-moderate COPD can affect 2 adrenoceptor function, and that erdosteine can exert a strong anti-scavenging and anti-lipid peroxidation activity.
A mild but significant effect on 2 -adrenoceptors was produced by erdosteine thus contributing to providing a partial enhancement of the original 2 -adrenoceptor-mediated bronchodilatation. While the anti-scavenging activity does not prove relevant from this point of view (actually N-acetylcysteine demonstrated almost no activity), it can be argued that the anti-inflammatory potentialities of erdosteine can play a crucial role in determining this effect. Further controlled studies are needed to demonstrate the persistency of these effects over time, and to assess their clinical relevance for the long-term treatment of COPD.
